ADCT vs CUBE · rev $70.8M vs P/E 25, rev $1.07B
ADC Therapeutics SA (ADCT) versus CubeSmart (CUBE) — a side-by-side from cached financials, not a winner call.
ADC Therapeutics SA (ADCT) is a biotechnology company listed on NYSE.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Latest reported ADCT revenue for 2024-12-31 was $70.8M. Net income was -$157.8M. Revenue was up 1.8% from 2023-12-31 to 2024-12-31. ADCT currently screens at market cap $141.2M.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
ADCT currently screens at market cap $141.2M. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Not investment advice. Open the ADCT and CUBE stock pages for the full models.
Not investment advice.